Transformative pain therapeutics

Changing the course of pain for patients who need it most

Who we are

Adynxx, located in San Francisco, is a clinical-stage biotechnology company developing a transformative technology platform addressing pain at its molecular roots. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.

Therapeutic approach

Provide safe, non-opioid, long-term pain reduction with a single administration

Clear mission

Developing transformative, first-in-class therapies to address significant unmet medical needs

Groundbreaking Science

A proprietary platform of non-opioid, disease-modifying oligonucleotide therapeutics

Tackling high unmet need

Focusing on patients who have the greatest need for innovative pain treatments

News & Publications

Dec 13, 2018
SAN FRANCISCO, Calif., December 13, 2018 -- Adynxx, Inc., a clinical-stage biotechnology company focused on developing transformative therapies for pain and inflammatory diseases, today announced receipt of Notice of Award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), for an award to support the clinical development of the company’s lead product candidate, brivoligide injection (brivoligide) for postoperative pain.

Meet our team

Experienced management team with a proven track record of success dedicated to improving the life of patients